Key opinion leaders in the field of multiple myeloma share a comprehensive discussion centered on clinical data behind both BCMA- and non–BCMA-targeting bispecifics within the treatment landscape.
EP. 1: BCMA-Targeting Bispecifics in Multiple Myeloma: TeclistamabApril 26th 2023
Opening its discussion on BCMA-targeting bispecific antibodies in multiple myeloma, a panel of expert oncologists highlights key clinical data behind teclistamab.
EP. 3: The Evolving Role of BCMA-Targeting Bispecifics in Multiple MyelomaMay 2nd 2023
Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.
EP. 4: Multiple Myeloma: Selecting Among the BCMA-Targeting TherapiesMay 2nd 2023
Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.
EP. 5: BCMA-Targeting Bispecifics in Multiple Myeloma: Safety ProfileMay 9th 2023
Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.
EP. 6: Non-BCMA-Targeting Bispecifics in Multiple Myeloma: TalquetamabMay 9th 2023
Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,
EP. 7: Non-BCMA-Targeting Bispecifics in Multiple Myeloma: CevostamabMay 16th 2023
A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.
EP. 8: The Evolving Role of Non-BCMA-Targeting Bispecifics in Multiple MyelomaMay 16th 2023
Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.
EP. 9: Multiple Myeloma: Use of Bispecifics in Challenging Patient PopulationsMay 23rd 2023
Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.